KinoPharma Inc.
KinoPharma is a next-generation antiviral drug development company dedicated to providing innovative medicines for high medical need areas, such as viral infections and neurodegenerative disorders. The company aims to develop and deliver new drugs quickly to patients worldwide, focusing on diseases like cervical cancer caused by HPV, and Alzheimer's disease. They utilize a novel drug discovery approach targeting host factors involved in virus replication and neurodegeneration, collaborating closely with academia, especially Kyoto University. KinoPharma's mission is to create medicines that do not currently exist, improving patient outcomes and societal health.
Industries
Nr. of Employees
small (1-50)
KinoPharma Inc.
705, Nihonbashi Life Science Building2, 3-11-5 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023, Japan
Patents
Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
US-10017524-B2
View DetailsCompound and pharmaceutical composition for neuropsychological disorder or malignant tumor
US-9745323-B2
View Details
Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
US-10017524-B2
View DetailsCompound and pharmaceutical composition for neuropsychological disorder or malignant tumor
US-9745323-B2
View DetailsProducts
Vaginal tablet for cervical intraepithelial neoplasia (CIN)
A self-administered vaginal tablet designed to act locally on the cervix to suppress HPV replication and promote repair of dysplastic cervical tissue; intended to treat CIN and prevent progression to cervical cancer.
Topical ointment for common warts (cutaneous HPV)
An ointment formulated for local application to common warts to inhibit HPV proliferation and promote regression of wart tissue; clinical trials reported reductions in lesion size and complete regression with twice-daily application.
Topical ointment candidate for condyloma acuminatum
A topical formulation intended to suppress HPV proliferation and repair dysplastic tissue in genital warts; Phase I trials in healthy volunteers have confirmed safety.
Vaginal tablet for cervical intraepithelial neoplasia (CIN)
A self-administered vaginal tablet designed to act locally on the cervix to suppress HPV replication and promote repair of dysplastic cervical tissue; intended to treat CIN and prevent progression to cervical cancer.
Topical ointment for common warts (cutaneous HPV)
An ointment formulated for local application to common warts to inhibit HPV proliferation and promote regression of wart tissue; clinical trials reported reductions in lesion size and complete regression with twice-daily application.
Topical ointment candidate for condyloma acuminatum
A topical formulation intended to suppress HPV proliferation and repair dysplastic tissue in genital warts; Phase I trials in healthy volunteers have confirmed safety.
Services
Collaborative R&D with universities to translate academic discoveries into clinical trials, including support for investigator-initiated studies.
Strategic partnerships for formulation development, API supply, co-development and commercialization of topical antiviral products.
Collaborative R&D with universities to translate academic discoveries into clinical trials, including support for investigator-initiated studies.
Strategic partnerships for formulation development, API supply, co-development and commercialization of topical antiviral products.
Expertise Areas
- Host-targeted antiviral drug discovery
- Clinical development for small-molecule therapeutics
- Topical and local drug delivery development
- Neurodegenerative small-molecule research (Dyrk1a)
Key Technologies
- Host-factor targeting antiviral approach
- Small-molecule kinase inhibition (Dyrk1a)
- Topical delivery systems (vaginal tablets, ointments)
- Animal disease models for papillomavirus and cognitive decline
News & Updates
Enrollment has started for a Phase II clinical trial for common warts caused by HPV. More details are available on ClinicalTrials.gov.
KinoPharma announced the start of a Phase 2 clinical trial for the treatment of cutaneous warts caused by HPV.
An interview discussing the company's efforts to develop new antiviral drugs to stop virus-infected cervical tissue cancer.
KinoPharma entered into a co-development and commercialization agreement with IWAKI SEIYAKU for HPV-related wart treatments.
Development of drugs for cervical intraepithelial neoplasia (CIN)
KinoPharma is developing a drug to treat CIN, a precancerous condition caused by HPV, with clinical trials underway in Japan and Korea.
Research on HPV and cervical cancer
The company focuses on developing antiviral drugs to eliminate HPV and prevent cervical cancer, which causes significant mortality among women.
Enrollment has started for a Phase II clinical trial for common warts caused by HPV. More details are available on ClinicalTrials.gov.
KinoPharma announced the start of a Phase 2 clinical trial for the treatment of cutaneous warts caused by HPV.
An interview discussing the company's efforts to develop new antiviral drugs to stop virus-infected cervical tissue cancer.
KinoPharma entered into a co-development and commercialization agreement with IWAKI SEIYAKU for HPV-related wart treatments.
Development of drugs for cervical intraepithelial neoplasia (CIN)
KinoPharma is developing a drug to treat CIN, a precancerous condition caused by HPV, with clinical trials underway in Japan and Korea.
Research on HPV and cervical cancer
The company focuses on developing antiviral drugs to eliminate HPV and prevent cervical cancer, which causes significant mortality among women.